

CURRICULUM VITAE AND LIST OF PUBLICATIONS

• Personal Details

Shiri Navon-Venezia

Date and place of birth: 20 October 1967, USA

Date of immigration: 1970

Regular military service: 8/1985 - 1/1988

Address (home): 12 Vitkin St. Hertzelia

P: 972-52-2201303 Email: shirinv@ariel.ac.il; s.navonvenezia@gmail.com

• Education

BSc 1988-1992 - Technion Institute of Technology, Haifa, Israel

Faculty of Biotechnology & Food Engineering

MSc 1992-1994 - (*Magna Cum Lauda*) - Tel Aviv University, Tel Aviv, Israel

Faculty of Life Science, Department of Molecular Microbiology & Biotechnology.

Supervisor: Prof. Eugene Rosenberg

PhD 1994-1998 - Tel Aviv University, Tel Aviv, Israel - Faculty of Life Science, Department of Molecular Microbiology & Biotechnology.

Supervisor: Prof. Eugene Rosenberg. Title of thesis: "Alasan, a novel bioemulsan of *Acinetobacter radioresistens* KA53"

• Employment History

2019-present Ariel University, The Adelson School of Medicine, Full Professor

2018-present Ariel University, Department of Molecular Biology, Full Professor

Head of the Lab of Bacterial Pathogens and Antibacterial Research

2013-2018 Ariel University, Department of Molecular Biology, Associate Professor

Head of the Lab of Bacterial Pathogens and Antibacterial Research

10/2012 Ariel University, Department of Molecular Biology, Senior Lecturer

Head of the Lab of Bacterial Pathogens and Antibacterial Research

2011-2012 Tel Aviv University, Sackler Faculty of Medicine, Department of Clinical Microbiology & Immunology, Senior Lecturer (Associate faculty)

- 2007- 2011** Tel Aviv University, Sackler Faculty of Medicine, Department of Clinical Microbiology & Immunology, Lecturer (Associate faculty)
- 1999- 2011** Tel Aviv Medical Center, Epidemiology Division, Senior Scientist
Head of the Lab of Molecular Epidemiology & Antimicrobial Research
- 1999- 2001** Post-Doc training, Tel Aviv Medical Center, Tel Aviv, Israel.
Epidemiology Division, Prof. Yehuda Carmeli

- **Professional Activities**

- (a) Positions in academic administration (departmental, faculty and university)

- 10/2020- 2023** Head of the Department of Molecular Biology, Faculty of Natural Sciences, Ariel University
- 2018- 2019** Head of the MSc. Program in Molecular Biology, Ariel University
- 2013- 2018** Department of Molecular Biology, Ariel University
Member in the Institutional Ethical Animal Committee
- 2015- Present** Department of Molecular Biology, Ariel University
Head of Department Search Committee

- (b) Professional functions outside universities/institutions

- 2019-2020** “Movilim bacademia” Program
- 2017-Present** Invited member in academic promotion and appointment committees in different universities and research institutes in Israel (Ministry of Health Laboratories, affiliated to TAU)
- 2017-Present** Israeli Council for Higher Education, Planning and Budgeting Committee (PBC), committee member for Postdoctoral scholarships from India and China
- 2016- Present** ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD).
- 2015** Organizer, ISM Fall Workshop, Kfar Giladi, Israel
"The microbiome in and around us"
- 2010- 2014** International European Network on carbapenemases
- 2007- 2011** International/EU International MOSAR study group
(Mastering Hospital Antimicrobial Resistance and its Spread into the Community)
- 2010** Organizer, ISM Fall Workshop, Ein-Gedi, Israel. "World of change: adaptive responses of microorganisms"
- (f) Membership in professional/scientific societies
- 2010- Present** ESCMID European Society Clinical Microbiology Infectious Diseases
- 2011- Present** European Expert Group on Carbapenemases

2008-Present Israel Long-term care facility carbapenem-resistant Enterobacteriaceae working group

1995- Present ISM-Israel society of Microbiology

2000- Present ASM- American Society of Microbiology

2011- 2013 ISM- Israel society of Microbiology, secretary

2009- 2013 ISM-Israel society of Microbiology, board member

- **Community volunteering**

- 'Top-Ariel' Program for excellent students - Scientific supervisor
- Technion mentoring program
- Masa student research mentor
- Alpha Project scientific mentor
- Popular science lectures in High schools in Herzliya

- **Educational activities**

- (a) Courses taught

Scientific Reading & Writing- Graduate- AU

Introduction to Microbiology- Molecular Biology and pre-Med Undergraduate- AU

Food & Water Microbiology- Undergraduate- AU

Food Toxicology- Undergraduate- AU

Virology- Undergraduate- AU

Molecular Biology Lab- Undergraduate- AU

Clinical Microbiology- Jointly taught- Sackler Medical School- TAU

Frontiers in Microbiology- Jointly taught- Graduate- Sackler Medical School- TAU

Infection and Inflammation- visiting lecturer- Zefat Medical School - Bar Ilan University

- (b) Research students

Graduated students:

2019 - Ziv Dor - MSc, AU

2019- Sapir Meninger – MSc, AU

2017 - Oryan Agranyoni- MSc, AU

2015 - Ayala Lumer-Wollman- MSc, AU

2015 - Eran Carasso- MSc, BIU (jointly supervised, Prof. Ehud Banin, BIU)

2015 - Livnat Naparstek- PhD, BIU (jointly supervised, Prof. Ehud Banin, BIU)

- 2011** - Azita Leavitt- PhD, TAU (jointly supervised, Prof. Yehuda Carmeli TAU)
2011 - Daphna Karfunkel- MSc, TAU (jointly supervised, Prof. Yehuda Carmeli TAU)
2010 - Moran Goren- MSc, TAU (jointly supervised, Prof. Yehuda Carmeli, TAU)
2006 - Yoav Barnea – MSc, TAU (jointly supervised, Prof. Yehuda Carmeli, TAU)

MD Basic science:

- 2010** - Ehud Arad- MD Basic Sciences TLMC
2008 -Sigal Ben-Shmuel-MD Basic Sciences TLMC (jointly supervised, Prof. Yehuda Carmeli, TAU)

• **Awards, Citations, Honors, Fellowships**

(a) Honors, Citation Awards (including during studies)

- 2018** Ariel University, Promotion of Gender Equality grant
2017 Ariel University, Dep. of Molecular Biology, Excellence in Teaching
2012 Tel-Aviv University, Sackler school of Medicine, Excellent lecturer
2009 ISM, Israel Society of Microbiology, ‘Sarov Prize’, Excellence in Clinical Microbiology Research
1996 Tel-Aviv University, ‘David and Paulina Trozky Scholarship for excellence’
1994 Tel Aviv University, ‘Arie Shenkar Scholarship for excellence’

(b) Fellowships

- 2001** ‘MSD’ - Etest Workshop, AB Biodisk, Solna, Sweden
1994 ‘Moshe Shilo Scholarship in Applied Microbiology’ -“Microbial-Diversity” summer course, at the Marine Biology Laboratory, Woods-Hole, MA, US
1994 ‘Howard Hughes Medical Institute Educational Program Scholarship’ - summer course in “Microbial-Diversity”, MBL, Woods-Hole, MA, US

• **Scientific Publications**

Authored books

(d) **Books Chapter**

- 1.** Rosenberg E, Navon-Venezia S, Zilber-Rosenberg I, and Ron EZ. Rate limiting steps in the microbial degradation of petroleum hydrocarbons. In: “Soil and aquifer pollution” Rubin H., Narkis N., Carberry J. (Eds.) p. 159-172. Springer-Verlag Press, Berlin. (24).

Articles

H-index- 53; Citations - 11,269

(a) Refereed articles and refereed letters in scientific journals

1. **Navon-Venezia S**, Zosim Z, Gottlieb A, Legmann R, Carmeli S, Ron EZ, Rosenberg E. 1995. Alasan, a new bioemulsifier from *Acinetobacter radioresistens*. Applied and Environmental Microbiology 61: 3240-3244. (IF 3.807, 241).
2. **Navon-Venezia S**, Banin E, Ron E Z, and Rosenberg E. 1998. The bioemulsifier alasan: role of protein in maintaining structure and activity. Applied Microbiology and Biotechnology 49: 382-384. (IF 3.42, 42).
3. Barkay T, **Navon-Venezia S**, Ron E Z and Rosenberg E. 1999. Enhancement of solubilization and biodegradation of polyaromatic hydrocarbons by the bioemulsifier alasan. Applied and Environmental Microbiology 65: 2697-2702. (IF 3.807, 285).
4. Toren A, **Navon-Venezia S**, Ron E Z and Rosenberg E. 2001. Emulsifying activity of purified alasan proteins. Applied and Environmental Microbiology 67:1102-1106. (IF 3.807, 113).
5. **Navon-Venezia S**, Feder R, Gaidukov L, Carmeli Y, and Mor A. 2002. Antibacterial properties of Dermaseptin S4 derivatives with in vivo activity. Antimicrobial Agents Chemotherapy 46: 689-694. (IF 4.302, 122).
6. **Navon-Venezia S**, Hammer-Munz O, Schwartz D, Turner D, Kozamnko B, and Carmeli Y. 2003. Occurrence and phenotypic characteristics of extended-spectrum beta-lactamases among members of the Enterobacteriaceae family at the Tel-Aviv Medical Center, Israel, and evaluation of diagnostic tests. Journal of Clinical Microbiology 41: 155-158. (IF 3.712, 65).
7. Ben-Ami R, **Navon-Venezia S**, Schwartz D, and Carmeli Y. 2003. Infection of a ventriculoatrial shunt with phenotypically variable *Staphylococcus epidermidis* masquerading by polymicrobial bacteremia with various coagulase-negative Staphylococci and *Kocuria varians*. Journal of Clinical Microbiology 41: 2444-2447. (IF 3.712, 35).
8. **Navon-Venezia S**, Ben-Ami R, Schwaber MJ, Leavitt A, Schwartz D, and Carmeli Y. 2004. Protocol for the accelerated detection of extended-spectrum beta-lactamase producing *Escherichia coli* and *Klebsiella pneumoniae* from blood cultures. European Journal Clinical Microbiology Infectious Diseases 23:200-202. (IF 2.727, 12).
9. Schwaber MJ, **Navon-Venezia S**, Leavitt A, Mekuzas Y, Hammer-Munz O, Schlesinger J, Schwartz D, Carmeli Y. 2004. Failure of broth-based tests to detect methicillin-resistant *Staphylococcus aureus* in a clinical specimen. European Journal Clinical Microbiology Infectious Diseases 23:348-351. (IF 2.727, 2).

10. **Navon-Venezia S**, Leavitt A, Ben-Ami R, Aharoni Y, Schwaber MJ, Schwartz D, and Carmeli Y. 2005. Evaluation of an accelerated protocol for the detection of extended-spectrum beta-lactamase-producing gram-negative bacilli (GNB) from positive blood cultures. Journal of Clinical Microbiology 43: 439-441. (IF 3.712, 17).
11. Ben-Ami R, **Navon-Venezia S**, Schwartz D, Schlezinger Y, Mekuzas Y, Carmeli Y. 2005. Erroneous Reporting of Coagulase-negative *Staphylococci* as *Kocuria* spp. by the Vitek 2 System. Journal of Clinical Microbiology 43:1448-1450. (IF 3.712, 46).
12. **Navon-Venezia S**, Ben-Ami R, Carmeli Y. 2005. Update on *Pseudomonas aeruginosa* and *Acinetobacter baumannii*. Current Opinion in Infectious Diseases 18:306-313. (IF 4.242, 373).
13. Abbo A, **Navon-Venezia S**, Hammer-Muntz O, Krichali T, Siegman-Igra Y, and Carmeli Y. 2005. Multidrug-resistant *Acinetobacter baumannii*. Emerging and Infectious Diseases 11: 22-29. (IF 8.222, 369).
14. Schlesinger J, **Navon-Venezia S**, Chmelnitsky I, Hammer-Münz O, Leavitt A, Gold HS, Schwaber MJ, Carmeli Y. 2005. Characterization of extended-spectrum beta-lactamases (ESBLs) among *Enterobacter* isolates in Tel Aviv. Antimicrobial Agents Chemotherapy 49: 1150-1156. (IF 4.302, 105).
15. Schwaber MJ, **Navon-Venezia S**, Schwartz D, Carmeli Y. 2005. High levels of antimicrobial co-resistance among extended-spectrum β -lactamase producing Enterobacteriaceae. Antimicrobial Agents Chemotherapy 49: 2137-2139. (IF 4.302, 149).
16. Chmelnitsky I, Carmeli Y, Leavitt A, Schwaber MJ, **Navon-Venezia S**. 2005. CTX-M-2 and a new CTX-M-39 enzyme are the major extended-spectrum beta-lactamases in multiple *Escherichia coli* clones isolated in Tel Aviv, Israel. Antimicrobial Agents Chemotherapy 49: 4745-4750. (IF 4.302, 77).
17. Neville LF, Barnea Y, Hammer-Munz O, Gur E, Kuzmenko B, Kahel-Raifer H, Eren R, Elkeles A, Murthy KGK, Szabó C, Salzman AL, Dagan S, Carmeli Y, **Navon-Venezia S**. 2005. Antibodies raised against N'-terminal *Pseudomonas aeruginosa* flagellin prevent mortality in lethal murine models of infection. International Journal of Molecular Medicine 16:165-171. (IF 2.341, 31).
18. Aloush V, **Navon-Venezia S**, Siegman-Igra Y, Cabili S, Carmeli Y. 2006. Multidrug-resistant *Pseudomonas aeruginosa*: risk factors and clinical impact. Antimicrobial Agents Chemotherapy 50: 43-48. (IF 4.841, 844).
19. Schwaber MJ, **Navon-Venezia S**, Chmelnitsky I, Leavitt A, Carmeli Y. 2006. Utility of the VITEK 2 Advanced Expert System for identification of extended-spectrum beta-lactamase

- production in *Enterobacter* spp. Journal of Clinical Microbiology 44:241-243. 2006 (IF 3.712, 24).
20. Ben-Ami R, Schwaber MJ, **Navon-Venezia S**, Schwartz D, Giladi M, Chmelnitsky I, Carmeli Y. 2006. Influx of extended-spectrum beta-lactamase-producing Enterobacteriaceae into the hospital. Clinical Infectious Diseases 42:925-934. (IF 8.216, 417).
 21. Schwaber MJ, **Navon-Venezia S**, Kaye KS, Ben-Ami R, Shwartz D, Carmeli Y. 2006. Clinical and economic impact of bacteremia with extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrobial Agents Chemotherapy 50:1257-1262. (IF 4.302, 499).
 22. Barnea Y, Carmeli Y, Kuzmenko B Gur E, Hammer-Muntz O, **Navon-Venezia S**. 2006. The establishment of a *Pseudomonas aeruginosa* infected burn-wound sepsis model and the effect of imipenem treatment. Annals of Plastic Surgery 56:674-679. (IF 1.596, 20).
 23. Stein M, **Navon-Venezia S**, Chmelnitsky I, Yossepowitch O, Kohelet D, Schwartz O, Agmon O, Somekh E. 2006. An outbreak of new, non multi drug resistant, methicillin resistant *Staphylococcus aureus* strain (SCCmec type IIIA variant-1) in NICU, transmitted by a staff member. Pediatric Infectious Disease Journal 25:557-559. (IF 2.486, 34).
 24. Barnea Y, Carmeli Y, Gur E, Kuzmenko B, Gat A, Neville L, Eren R, Dagan S, **Navon-Venezia S**. 2006. Efficacy of antibodies against the N-terminal of *Pseudomonas aeruginosa* flagellin for treating infections in a murine burn wound model. Plastic and Reconstructive Surgery (IF 3.784, 12).
 25. **Navon-Venezia S**, Chmelnitsky I, Leavitt A, Schwaber MJ, Schwartz D, Carmeli Y. 2006. Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem resistant *Escherichia coli* clones in Israel. Antimicrobial Agents Chemotherapy 50:3098-3101. (IF 4.302, 235).
 26. Zimhony O, Chmelnitsky I, Bardenstein R, Goland S, Hammer Muntz O, **Navon Venezia S**, Carmeli Y. 2006. Endocarditis caused by extended-spectrum-beta-lactamase-producing *Klebsiella pneumoniae*: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility. Antimicrobial Agents Chemotherapy 50:3179-3182. (IF 4.302, 62).
 27. Regev-Yochay G, Carmeli Y, Raz M, Pinco E, Etienne J, Leavitt A, Rubinstein E, **Navon-Venezia S**. 2006. Prevalence and genetic relatedness of community-acquired methicillin-resistant *Staphylococcus aureus* in Israel. European Journal Clinical Microbiology Infectious Disease 25:719-722. (IF 2.544, 20).

28. Vasilev V, Japheth R, Yishai R, Andorn N, Valinsky L, **Navon-Venezia S**, Chmelnitsky I, Carmeli Y, Cohen D. 2007. Extended-spectrum beta-lactamase-producing *Shigella* strains in Israel, 2000-2004. European Journal Clinical Microbiology Infectious Disease 26:189-194. (IF 2.866, 27).
29. Marchaim D, **Navon-Venezia S**, Schwartz D, Tarabeia J, Fefer I, Schwaber MJ, Carmeli Y. 2007. Surveillance cultures and duration of carriage of multidrug-resistant *Acinetobacter baumannii*. Journal of Clinical Microbiology 45:1551-1555. (IF 3.712, 138).
30. **Navon-Venezia S**, Leavitt A, Carmeli Y. 2007. High tigecycline resistance in multidrug-resistant *Acinetobacter baumannii*. Journal of Antimicrobial Chemotherapy 59:772-774. (IF 5.173, 321).
31. Radzishovsky IS, Rotem S, Bourdetsky D, **Navon-Venezia S**, Carmeli Y, Mor A. 2007. Improved antimicrobial peptides based on acyl-lysine oligomers. Nature Biotechnology 25:657-659. (IF 41.667, 240).
32. Leavitt A, **Navon-Venezia S**, Chmelnitsky I, Schwaber MJ, Carmeli Y. 2007. Emergence of KPC-2 and KPC-3 in carbapenem-resistant *Klebsiella pneumoniae* strains in an Israeli hospital. Antimicrobial Agents Chemotherapy 51:3026-3029. (IF 4.302, 356).
33. Marchaim D, **Navon-Venezia S**, Leavitt A, Chmelnitsky I, Schwaber MJ, Carmeli Y. 2007. Molecular and epidemiologic study of polyclonal outbreaks of multidrug-resistant *Acinetobacter baumannii* infection in an Israeli hospital. Infection Control Hospital Epidemiology 28:945-950. (IF 3.55, 53).
34. Abbo A, Carmeli Y, **Navon-Venezia S**, Siegman-Igra Y, Schwaber MJ. 2007. Impact of multi-drug-resistant *Acinetobacter baumannii* on clinical outcomes. European Journal Clinical Microbiology Infectious Disease 26:793-800. (IF 2.866, 124).
35. Chmelnitsky I, **Navon-Venezia S**, Leavitt A, Somekh E, Regev-Yochai G, Chowers M, Shitrit P, Carmeli Y. 2007. SCCmec and spa types of methicillin-resistant *Staphylococcus aureus* strains in Israel. Detection of SCCmec type V. European Journal Clinical Microbiology Infectious Disease 27:385-390. (IF 2.544, 20).
36. Schwaber MJ, Klarfeld-Lidji S, **Navon-Venezia S**, Schwartz D, Leavitt A, Carmeli Y. 2007. Predictors of carbapenem-resistant *Klebsiella pneumoniae* acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrobial Agents Chemotherapy 52:1028-1033. (IF 4.302, 531).
37. Marchaim D, **Navon-Venezia S**, Schwaber MJ, Carmeli Y. 2008. Isolation of imipenem-resistant *Enterobacter* species: emergence of KPC-2 carbapenemase, molecular

- characterization, epidemiology, and outcomes. Antimicrobial Agents Chemotherapy 52:1413-1418. (IF 4.302, 192).
38. Rotem S, Radzishovsky IS, Bourdetsky D, **Navon-Venezia S**, Carmeli Y, Mor A. 2008. Analogous oligo-acyl-lysines with distinct antibacterial mechanisms. FASEB Journal 22:2652-2661. (IF 5.498, 59).
39. **Navon-Venezia S**, Chmelnitsky I, Leavitt A, Carmeli Y. 2008. Dissemination of the CTX-M-25 family beta-lactamases among *Klebsiella pneumoniae*, *Escherichia coli* and *Enterobacter cloacae* and identification of the novel enzyme CTX-M-41 in *Proteus mirabilis* in Israel. Journal of Antimicrobial Chemotherapy 62:289-295. (IF 5.173, 50).
40. Chmelnitsky I, **Navon-Venezia S**, Strahilevitz J, Carmeli Y. 2008. Plasmid-mediated qnrB2 and carbapenemase gene *bla*(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible *Enterobacter cloacae* isolates. Antimicrobial Agents Chemotherapy 52:2962-2965. (IF 4.302, 52).
41. Sahly H, **Navon-Venezia S**, Roesler L, Hay A, Carmeli Y, Podschun R, Hennequin C, Forestier C, Ofek I. 2008. Extended-spectrum beta-lactamase production is associated with an increase in cell invasion and expression of fimbrial adhesins in *Klebsiella pneumoniae*. Antimicrobial Agents Chemotherapy 52:3029-3034. (IF 4.302, 64).
42. Barnea Y, Carmeli Y, Kuzmenko B, **Navon-Venezia S**. 2008. *Staphylococcus aureus* mediastinitis and sternal osteomyelitis following median sternotomy in a rat model. Journal of Antimicrobial Chemotherapy 62:1339-1343. (IF 5.173, 15).
43. Woodford N, Zhang J, Warner M, Kaufmann ME, Matos J, Macdonald A, Brudney D, Sompolinsky D, **Navon-Venezia S**, Livermore DM. 2008. Arrival of *Klebsiella pneumoniae* producing KPC carbapenemase in the United Kingdom. Journal of Antimicrobial Chemotherapy 62:1261-1264. (IF 5.173, 143).
44. Barnea Y, Carmeli Y, Neville LF, Kahel-Reifer H, Eren R, Dagan S, **Navon-Venezia S**. 2008. Therapy with anti-flagellin-A monoclonal antibody limits *Pseudomonas aeruginosa* invasiveness in a mouse burn wound sepsis model. Burns 35:390-396. (IF 2.056, 28).
45. **Navon-Venezia S**, Leavitt A, Schwaber MJ, Rasheed JK, Srinivasan A, Patel JB, Carmeli Y; Israeli KPC Kpn Study Group. 2008. First report on a hyper-epidemic clone of KPC-3-producing *Klebsiella pneumoniae* in Israel genetically related to a strain causing outbreaks in the United States. Antimicrobial Agents Chemotherapy 53:818-820. (IF 4.302, 224).
46. Leavitt A, Chmelnitsky I, Colodner R, Ofek I, Carmeli Y, **Navon-Venezia S**. 2009. Ertapenem resistance among extended spectrum beta-lactamases producing *Klebsiella pneumoniae*. Journal of Clinical Microbiology 47:969-974. (IF 3.712, 63).

47. Benenson S, **Navon-Venezia S**, Carmeli Y, Adler A, Strahilevitz J, Moses AE, Block C. 2009. Carbapenem-resistant *Klebsiella pneumoniae* endocarditis in a young adult successful treatment with gentamicin and colistin. International Journal of Infectious diseases 13:e295-298. (IF 2.532, 36).
48. Kitchel B, Rasheed JK, Patel JB, Srinivasan A, **Navon-Venezia S**, Carmeli Y, Brolund A, Giske CG. 2009. Molecular epidemiology of KPC-producing *Klebsiella pneumoniae* isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrobial Agents Chemotherapy 53:3365-3370. (IF 4.302, 543).
49. Calderon-Margalit R, **Navon-Venezia S**, Gefen D, Amitai Z, Barda R, Vulikh I, Sompolinsky D. 2009. Biennial hyper epidemic shigellosis in an observant Jewish community. Epidemiology and Infection 14:1-9. (IF 2.075, 5).
50. Chmelnitsky I, Hermesh O, **Navon-Venezia S**, Strahilevitz J, Carmeli Y. 2009. Detection of aac(6)-Ib-cr in KPC-producing *Klebsiella pneumoniae* isolates from Tel Aviv, Israel. Journal Antimicrobial Chemotherapy 64:718-722. (IF 5.489, 32).
51. Schechner V, Straus-Robinson K, Schwartz D, Pfeffer I, Tarabeia J, Moskovich R, Chmelnitsky I, Schwaber MJ, Carmeli Y, **Navon-Venezia S**. 2009. Evaluation of PCR-based testing for surveillance of KPC-producing carbapenem-resistant members of the Enterobacteriaceae family. Journal of Clinical Microbiology 47:3261-3265. (IF 3.712, 127).
52. Regev-Yochay G, Raz M, Carmeli Y, Shainberg B, **Navon-Venezia S**, Pinco E, Leavitt A, Keller N, Rahav G, Malley R, Rubinstein E. 2009. Parental *Staphylococcus aureus* carriage is associated with Staphylococcal carriage in young children. Pediatrics Infectious Diseases Journal 28:960-965. (IF 3.577, 28)
53. Leavitt A, Chmelnitsky I, Ofek I, Carmeli Y, **Navon-Venezia S**. 2009. Plasmid pKpQIL encoding KPC-3 and TEM-1 confers carbapenem resistance in an extremely drug-resistant epidemic *Klebsiella pneumoniae* strain. Journal Antimicrobial Chemotherapy 65:243-248. (IF 5.439, 67).
54. Reddy T, Chopra T, Marchaim D, Pogue JM, Alangaden G, Salimnia H, Boikov D, **Navon-Venezia S**, Akins R, Selman P, Dhar S, Kaye KS. 2010. Trends in antimicrobial resistance of *Acinetobacter baumannii* isolates from a metropolitan Detroit health system. Antimicrobial Agents Chemotherapy 54:2235-2238. (IF 4.302, 61).
55. Leavitt A, Carmeli Y, Chmelnitsky I, Goren MG, Ofek I, **Navon-Venezia S**. 2010. Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing *Klebsiella pneumoniae* strains in Israel. Antimicrobial Agents Chemotherapy 54: 3002-3006. (IF 4.302, 93).

56. Goren MG, **Navon-Venezia S**, Chmelnitsky I, Carmeli Y. 2010. Carbapenem Resistant KPC-2-producing *Escherichia coli* in Tel Aviv Medical Center: 2005-2008. Antimicrobial Agents Chemotherapy 54: 2687-2691. (IF 4.302, 37).
57. Cuzon G, Naas T, Truong H, Villegas MV, Wisell KT, Carmeli Y, Gales AC, **Navon-Venezia S**, Quinn JP, Nordmann P. 2010. Worldwide Diversity of *Klebsiella pneumoniae* that produce β -Lactamase *bla*_{KPC-2} Gene. Emerging Infectious Diseases. 16: 1349-1356. (IF 8.222, 361).
58. Goren MG, Carmeli Y, Schwaber MJ, Chmelnitsky I, Schechner V, **Navon-Venezia S**. 2010. Transfer of carbapenem-resistant plasmid from *Klebsiella pneumoniae* ST258 to *Escherichia coli* in patient. Emerging Infectious Diseases 16:1014-1017. 2010 (IF 8.222, 101).
59. Leavitt A, Chmelnitsky I, Carmeli Y, **Navon-Venezia S**. 2010. Complete nucleotide sequence of KPC-3-encoding plasmid pKpQIL in the epidemic *Klebsiella pneumoniae* sequence type 258. Antimicrobial Agents Chemotherapy 54: 4493-4496. (IF 4.302, 81).
60. Lopez JA, Correa A, **Navon-Venezia S**, Correa AL, Torres JA, Briceno DF, Montealegre MC, Quinn JP, Carmeli Y, Villegas MV. 2011. Intercontinental spread from Israel to Colombia of a KPC-3-producing *Klebsiella pneumoniae* strain. Clinical Microbiology Infection 17:52-56. (IF 5.292, 70).
61. Marchaim D, Chopra T, Pogue JM, Perez F, Hujer AM, Rudin S, Endimiani A, **Navon-Venezia S**, Hothi J, Slim J, Blunden C, Shango M, Lephart PR, Salimnia H, Reid D, Moshos J, Hafeez W, Bheemreddy S, Chen TY, Dhar S, Bonomo RA, Kaye KS. 2011. Outbreak of colistin resistant, carbapenem resistant *Klebsiella pneumoniae* in Metropolitan Detroit, Michigan. Antimicrobial Agents Chemotherapy 55: 593-599. (IF 4.302, 215).
62. Goren MG, Chmelnitsky I, Carmeli Y, **Navon-Venezia S**. 2011. Plasmid-encoded OXA-48 in *Escherichia coli* from Israel. Journal Antimicrobial Chemotherapy 66:672-673. (IF 5.439, 32).
63. Adler A, **Navon-Venezia S**, Moran-Gilad J, Marcos E, Schwartz D, Carmeli Y. 2011. Laboratory and clinical evaluation of screening agar plates for the detection of carbapenem resistant Enterobacteriaceae from surveillance rectal swabs. Journal of Clinical Microbiology 49:2239-2242. (IF 3.712, 105)
64. Schechner V, Kotlovsky T, Tarabeia J, Kazma M, Schwartz D, **Navon-Venezia S**, Carmeli Y. 2011. Predictors of rectal carriage of carbapenem-resistant Enterobacteriaceae (CRE) among patients with known CRE carriage at their next hospital encounter. Infection Control Hospital Epidemiology 32:497-503. (IF 3.55, 57).

65. Carmeli Y, Lidji SK, Shabtai E, **Navon-Venezia S**, Schwaber MJ. 2011. The effect of group I versus group II carbapenems on imipenem-resistant *Pseudomonas aeruginosa*: an ecological study. Diagnostic Microbiology and Infectious Diseases 70:367-372. (IF 2.401, 34).
66. Moran Gilad J, Carmeli Y, Schwartz D, **Navon-Venezia S**. 2011. Laboratory evaluation of the CHROMagar KPC medium for identification of carbapenem-nonsusceptible Enterobacteriaceae. Diagnostic Microbiology and Infectious Diseases 70:565-567. (IF 2.401, 36).
67. Ben David D, Masarwa S, **Navon-Venezia S**, Smollan G, Mishali H, Fridental I, Rubinovitch B, Carmeli Y and Schwaber MJ. 2011. Carbapenem resistant *Klebsiella pneumoniae* in post-acute-care facilities in Israel. Infection Control Hospital Epidemiology 32:845-853. (IF 3.55, 69).
68. Schwaber MJ, Masarwa S, **Navon-Venezia S**, Kandlik Y, Chmelnitsky I, Smollan G, Glick R, Neria G, Carmeli Y. 2011. High prevalence of methicillin-resistant *Staphylococcus aureus* among residents and staff of long-term care facilities, involving joint and parallel evolution. Clinical Infectious Diseases 53:910-913. (IF 8.216, 16).
69. Adler A, Shklyar M, Schwaber MJ, **Navon-Venezia S**, Dhaher Y, Edgar R, Solter E, Benenson S, Masarwa S, Carmeli Y. 2011. Introduction of OXA-48-producing Enterobacteriaceae to Israeli hospitals by medical tourism. Journal Antimicrobial Chemotherapy 66:2763-2766. (IF 5.439, 47).
70. Moran-Gilad J, Schwartz D, **Navon-Venezia S**, Carmeli Y. 2012. Laboratory evaluation of the ESwab transport system for the recovery of carbapenem-resistant *Acinetobacter baumannii*. European Journal Clinical Microbiology Infectious Disease 31:1429-1433. (IF 2.544, 4).
71. Adler A, Chmelnitsky I, Shitrit P, Sprecher H, **Navon-Venezia S**, Embon A, Khabra E, Paitan Y, Keren L, Halperin E, Carmeli Y, Schwaber MJ. 2012. Molecular epidemiology of methicillin-resistant *Staphylococcus aureus* in Israel: dissemination of global clones and unique features. Journal of Clinical Microbiology 50:134-137. (IF 3.712, 16).
72. Naparstek L, Carmeli Y, Chmelnitsky I, Banin E, **Navon-Venezia S**. 2012. Reduced susceptibility to chlorhexidine among extremely-drug-resistant strains of *Klebsiella pneumoniae*. Journal of Hospital Infection 81:15-19. (IF 2.782, 63).
73. Cantón R, Akóva M, Carmeli Y, Giske CG, Glupczynski Y, Gniadkowski M, Livermore DM, Miriagou V, Naas T, Rossolini GM, Samuelsen Ø, Seifert H, Woodford N, Nordmann P; European Network on Carbapenemases*. 2012. Rapid evolution and spread of

- carbapenemases among Enterobacteriaceae in Europe. Clinical Microbiology Infection 18:413-431. (IF 5.197). *I'm a member in the European Network on carbapenemases
74. Nordmann P, Gniadkowski M, Giske CG, Poirel L, Woodford N, Miriagou V; European Network on Carbapenemases*. 2012. Identification and screening of carbapenemase-producing Enterobacteriaceae. Clinical Microbiology Infection 18:432-438. (IF 5.292). *I'm a member in the European Network on carbapenemases
75. Bilavsky E, Lerman Y, Rabinovich A, Salomon J, Lawrence C, Rossini A, Salvia A, Samsó JV, Fierro J, Hochman M, Kazma M, Klein A, Schwaber MJ, Carmeli Y; MOSAR WP5 study team*. 2012. Carriage of methicillin-resistant *Staphylococcus aureus* on admission to European rehabilitation centers—a prospective study. Clinical Microbiology Infection 18:E164-169. (IF 5.292). * I'm a member in the MOSAR WP5 study team.
76. Schechner V, Kotlovsky T, Kazma M, Mishali H, Schwartz D, **Navon-Venezia S**, Schwaber MJ, Carmeli Y. 2012. Asymptomatic rectal carriage of *bla*(KPC) producing carbapenem-resistant Enterobacteriaceae: who is prone to become clinically infected? Clinical Microbiology Infection 19:451-456. (IF 5.292, 87).
77. Adler A, Gniadkowski M, Baraniak A, Izdebski R, Fielt J, Hryniewicz W, Malhotra-Kumar S, Goossens H, Lammens C, Lerman Y, Kazma M, Kotlovsky T, Carmeli Y; MOSAR WP5 and WP2 study groups*. 2012. Transmission dynamics of ESBL-producing *Escherichia coli* clones in rehabilitation wards at a tertiary care center. Clinical Microbiology Infection (12):E497-505. (IF 5.292). *I'm a member of the MOSAR Study group.
78. Chmelnitsky I, Shklyar M, Hermesh O, **Navon-Venezia S**, Edgar R, Carmeli Y. 2013. Unique genes identified in the epidemic extremely drug-resistant KPC-producing *Klebsiella pneumoniae* sequence type 258. Journal Antimicrobial Chemotherapy 68:74-83. (IF 5.439, 40).
79. Arad E*, **Navon-Venezia S***, Gur E, Kuzmenko B, Glick R, Frenkiel-Krispin D, Kramer E, Carmeli Y, Barnea Y. ***Equal contribution**. 2013. Novel Rat Model of Methicillin-Resistant *Staphylococcus aureus*-Infected Silicone Breast Implants: A Study of Biofilm Pathogenesis. Plastic Reconstructive Surgery 131:205-214. (IF 3.328, 21).
80. Izdebski R, Baraniak A, Fielt J, Adler A, Kazma M, Salomon J, Lawrence C, Rossini A, Salvia A, Vidal Samsó J, Fierro J, Paul M, Lerman Y, Malhotra-Kumar S, Lammens C, Goossens H, Hryniewicz W, Brun-Buisson C, Carmeli Y, Gniadkowski M; MOSAR WP2 and WP5 Study Groups*. 2013. Clonal structure, extended-spectrum β -lactamases, and acquired AmpC-type Cephalosporinases of *Escherichia coli* populations colonizing patients in rehabilitation centers

in four countries. Antimicrobial Agents Chemotherapy 57:309-316. (IF 4.302). *I'm a member of the MOSAR Study group.

81. Lerner A, Adler A, Abu-Hanna J, Meitus I, **Navon-Venezia S**, Carmeli Y. 2013. Environmental contamination by carbapenem-resistant Enterobacteriaceae. Journal of Clinical Microbiology 51:177-181. (IF 3.712, 51).
82. Adler A, Baraniak A, Izdebski R, Fiett J, Gniadkowski M, Hryniewicz W, Salvia A, Rossini A, Goossens H, Malhotra S, Lerman Y, Elenbogen M, Carmeli Y; MOSAR WP5 & WP2 study groups*. A binational cohort study of intestinal colonization with extended-spectrum β -lactamase-producing *Proteus mirabilis* in patients admitted to rehabilitation centers. Clinical Microbiology Infection 19:E51-58. 2013 (IF 5.292, 0) *I'm a member of the MOSAR Study group.
83. Schwaber MJ, **Navon-Venezia S**, Masarwa S, Tirosh-Levy S, Adler A, Chmelnitsky I, Carmeli Y, Klement E, Steinman A. 2013. Clonal transmission of a rare methicillin-resistant *Staphylococcus aureus* genotype between horses and staff at a veterinary teaching hospital. Veterinary Microbiology 162:907-1120. (IF 2.628, 21).
84. Lerner A, Romano J, Chmelnitsky I, **Navon-Venezia S**, Edgar R, Carmeli Y. 2013. Rectal swabs are suitable for quantifying the carriage load of KPC-producing carbapenem-resistant Enterobacteriaceae (CRE). Antimicrobial Agents Chemotherapy 57:1474-1479. (IF 4.302, 33).
85. Feldman N, Adler A, Molshatzki N, **Navon-Venezia S**, Khabra E, Cohen D, Carmeli Y. 2013. Gastrointestinal colonization by KPC-producing *Klebsiella pneumoniae* following hospital discharge: duration of carriage and risk factors for persistent carriage. Clinical Microbiology Infection 19: E190-196. (IF 5.292, 70).
86. Baraniak A, Izdebski R, Fiett J, Sadowy E, Adler A, Kazma M, Salomon J, Lawrence C, Rossini A, Salvia A, Vidal Samsó J, Fierro J, Paul M, Lerman Y, Malhotra-Kumar S, Lammens C, Goossens H, Hryniewicz W, Brun-Buisson C, Carmeli Y, Gniadkowski M; MOSAR WP2 and WP5 Study Groups*. 2013. Comparative population analysis of *Klebsiella pneumoniae* strains with extended-spectrum β -lactamases colonizing patients in rehabilitation centers in four countries. Antimicrobial Agents Chemotherapy 57:1992-1997. *I'm a member of the MOSAR Study group. (IF 4.302, 0).
87. Bilavsky E, Pfeffer I, Tarabeia J, Schechner V, Abu-Hanna J, Grisaru-Soen G, Schwartz D, **Navon-Venezia S**, Carmeli Y. 2013. Outbreak of multidrug-resistant *Pseudomonas aeruginosa* infection following urodynamic studies traced to contaminated transducer. Journal Hospital Infection 83:344-346. (IF 2.782, 6).

88. Karfunkel D, Carmeli Y, Chmelnitsky I, Kotlovsky T, **Navon-Venezia S**. 2013. The emergence and dissemination of CTX-M-producing *Escherichia coli* sequence type 131 causing community-onset bacteremia in Israel. European Journal Clinical Microbiology Infectious Diseases 32: 513-521. (IF 2.727, 31).
89. Barnea Y, **Navon-Venezia S**, Kuzmenko B, Artzi N, Carmeli Y. 2014. Ceftobiprole medocartil is an effective treatment against methicillin-resistant *Staphylococcus aureus* (MRSA) mediastinitis in a rat model. European Journal Clinical Microbiology Infectious Diseases 33:325-329. (IF 2.727, 5).
90. Naparstek L, Carmeli Y, **Navon-Venezia S***, Banin E.* ***Equal contribution** 2014. Biofilm formation and susceptibility to gentamicin and colistin in extremely drug resistant KPC-producing *Klebsiella pneumoniae*. Journal of Antimicrobial Chemotherapy.69:1027-1034. (IF 5.173, 36).
91. Chmelnitsky I, Shklyar M, Leavitt A, Sadovsky E, **Navon-Venezia S**, Ben Dalak M, Edgar R, Carmeli Y. 2014. Mix and match of KPC-2 encoding plasmids in Enterobacteriaceae-comparative genomics. Diagnostic Microbiology and Infectious Disease. 79:255-60. (IF 2.401, 22).
92. Ben-David D, Schwaber MJ, Adler A, Masarwa S, Edgar R, **Navon-Venezia S**, Schwartz D, Porat N, Kotlovsky T, Polivkin N, Weinberg I, Lazary A, Ohana N, Dagan R. 2014. Persistence and complex evolution of fluoroquinolone-resistant *Streptococcus pneumoniae* clone. Emerging Infectious Diseases 20:799-805. (IF 8.222, 5).
93. Moran-Gilad J, Adler A, Schwartz D, **Navon-Venezia S**, Carmeli Y. 2014. Laboratory evaluation of different agar media for isolation of carbapenem-resistant *Acinetobacter* spp. European Journal Clinical Microbiology Infectious Diseases 33: 1909-1913. (IF 2.727, 3).
94. Adler A, Hussein O, Ben-David D, Masarwa S, **Navon-Venezia S**, Schwaber MJ, Carmeli Y; Post-Acute-Care Hospital Carbapenem-Resistant Enterobacteriaceae Working Group. 2015. Persistence of *Klebsiella pneumoniae* ST258 as the predominant clone of carbapenemase-producing Enterobacteriaceae in post-acute-care hospitals in Israel, 2008-13. Journal of Antimicrobial Chemotherapy 70(1):89-92. (IF 5.173, 34).
95. Izdebski R, Baraniak A, Herda M, Fielt J, Bonten MJM, Carmeli Y, Goossens H, Hryniewicz W, Brun-Buisson C, Gniadkowski M. 2015. MOSAR WP2 and WP5 Study Groups*. MLST reveals potentially high-risk international clones of *Enterobacter cloacae*. Journal of Antimicrobial Chemotherapy 70(1):48-56. *I'm a member of the MOSAR Study group. (IF 5.173, 42).

96. Kaplan E, Sela N, Doron-Faigenboim A, **Navon-Venezia S**, Jurkevitch E, Cytryn E. 2015. Genomic and Functional Characterization of qnr-Encoding Plasmids from Municipal Wastewater Biosolid *Klebsiella pneumoniae* Isolates. Frontiers in Microbiology 6:1354 (IF 4.076, 4).
97. Papagiannitsis CC, Izdebski R, Baraniak A, Fiett J, Herda M, Hrabák J, Derde LPG, Bonten MJM, Carmeli Y, Goossens H, Hryniewicz W, Brun-Buisson C, Gniadkowski M. MOSAR WP2 and WP5 Study Groups*. 2015. Survey of metallo- β -lactamase-producing Enterobacteriaceae colonizing patients in European ICUs and rehabilitation units, 2008–11. Journal of Antimicrobial Chemotherapy 70(7):1981-1988. *I'm a member of the MOSAR Study group. (IF 5.173, 17).
98. Tirosh-Levy S, Steinman A, Carmeli Y, Klement E, **Navon-Venezia S**. 2015. Prevalence and risk factors for colonization with methicillin resistant *Staphylococcus aureus* and other *Staphylococci* species in hospitalized and farm horses in Israel. Preventive Veterinary Medicine 122(1):135-144. (IF 1.987, 8).
99. Barnea Y, Lerner A, Aizic A, Navon-Venezia S, Rachi E., Dunne MW, Puttagunta S, Carmeli Y. 2016. Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitis. Journal of Antimicrobial Chemotherapy 71(2):460-463. (IF 5.173, 4).
100. Carasso E, Salmon-Divon M, Carmeli Y, Banin E, **Navon-Venezia S**. 2016. Draft genome sequences of two multidrug-resistant extended-spectrum- β -lactamase-producing *Klebsiella pneumoniae* strains causing bloodstream infections. Genome Announcements 4 (1), e01533-15 (1).
101. **Navon-Venezia S**, Kondratyeva K, Carattoli A. 2017. *Klebsiella pneumoniae*: a major worldwide source and shuttle for antibiotic resistance. FEMS Microbiology Reviews. 41(3):252-275. (IF 12.198, 217).
102. Kondratyeva K, Wollman A, Gerlitz G, **Navon-Venezia S**. 2017. Adhesion and invasion to epithelial-cell and motility of ESBL-producing *Escherichia coli* reveal ST131 superiority: A comparative in vitro study of extraintestinal pathogenic *E. coli* lineages. Journal of Medical Microbiology. 66(9):1350-1357. (IF 2.159).
103. Barnea Y, Hammond DC, Geffen Y, **Navon-Venezia S**, Goldberg K. 2018. Plasma Activation of a Breast Implant Shell in Conjunction With Antibacterial Irrigants Enhances Antibacterial Activity. Aesthetic Surgical Journal. 38(11):1188-1196. (IF 2.697, 3).
104. Brosh-Nissimov T, **Navon-Venezia S**, Keller N, Amit S. 2019. Risk analysis of antimicrobial resistance in outpatient urinary tract infections of young healthy adults. Journal of Antimicrobial Chemotherapy 74 (2):499-502.

105. Fainstein N, Tyk R, Touloumi O, Lagoudaki R, Goldberg Y, Agranyoni O, **Navon-Venezia S**, Katz A, Grigoriadis N, Ben-Hur T, Einstein O. 2019. Exercise intensity-dependent immunomodulatory effects on encephalomyelitis. Ann Clinical Translational Neurology. 6(9):1647-1658.
106. Shnaiderman-Torban A, Steinman A, Meidan G, Paitan Y, Abu Ahmad W, **Navon-Venezia S**. 2019. Petting Zoo Animals as an Emerging Reservoir of Extended-Spectrum β -Lactamase and AmpC-Producing Enterobacteriaceae. Frontiers in Microbiology. 10:2488.
107. Shnaiderman-Torban A, Paitan Y, Arielly H, Kondratyeva K, Tirosh-Levi S, Abells-Sutton G, **Navon-Venezia S**, Steinman A. 2019. Extended-spectrum β -lactamase-producing Enterobacteriaceae in hospitalized neonatal foals: Prevalence, risk factors for shedding and association with infection. Animals 9(9):600.
108. Kondratyeva K, Salmon-Divon M, **Navon-Venezia S**. 2020. Meta-analysis of pandemic *Escherichia coli* ST131 plasmidome proves restricted plasmid-clade associations. Scientific Reports 10: 36.
109. Shnaiderman-Torban A, **Navon-Venezia S**, Dor Z, Paitan Y, Arielly H, Abu Ahmad W, Kelmer G, Fulde M, Steinman A. 2020. Extended-Spectrum β -lactamase-Producing Enterobacteriaceae Shedding in Farm Horses Versus Hospitalized Horses: Prevalence and Risk Factors. Animals (Basel) 10(2): 282.
110. Yagel Y, Sestito S, Motro Y, Shnaiderman-Torban A, Khalfin B, Sagi O, **Navon-Venezia S**, Steinman A, Moran-Gilad J. 2020. Genomic Characterization of Antimicrobial Resistance, Virulence, and Phylogeny of the Genus Ochrobactrum. Antibiotics 9:177.

• **Lectures and Presentations at Meetings and Invited Seminars not followed by Published Proceedings**

(a) Invited lectures and presentations at meetings and workshops

1. April 2020. “Emergence of multiple ESBL-producing *Salmonella enterica* serovars in hospitalized horses due to an epidemic spread of a CTX-M-3 plasmid pSIEL-3”. European Clinical Microbiology & Infectious Diseases, (ECCMID), Paris, France.
2. April 2019. Press Release. European Clinical Microbiology & Infectious Diseases, (ECCMID), Amsterdam, NL.
3. Dec 2018. “Gut microbiota shapes social behavior by impacting adipose metabolism and mediating inflammation response”. The Eli Hurvitz Microbiome Israel Workshop from Bench to Bedside, Faculty of Medicine, Safed, Israel.

4. Dec 2018. "Emergence of Antibiotic resistance in Pathogens". The Annual meeting of Bovine Sciences, Jerusalem. Israel.
5. June 2018. "Antibiotic resistance: challenges and future prospects". The Council for Regulation of Research into Biological Disease Agents, TAU, Israel
6. May 2018. "Antibiotic resistance in companion animals". Infectious Diseases and One Health in the Negev meeting. Soroka Medical Center, BGU, Beer-Sheva, Israel.
7. Nov 2017. "Genes involved in serum resistance in *Klebsiella pneumoniae*". ISM fall workshop, Genosar, Israel.
8. Nov 2017. "Antibiotic Resistant Pathogens causing Urinary Tract Infections (UTIs) in Israeli Soldiers: Prevalence and Molecular Features". IDF Annual meeting, Ariel, Israel.
9. Oct 2017. "Antibiotic Resistance in Companion animals: A One-Health Threat?". International Conference on Clinical & Pharmaceutical Microbiology, Rome, Italy.
10. Mar 2017. "The role of the gut microbiome in shaping depressive-like behavior". ISBP, Israel Society of Biological Psychiatry annual meeting, Kfar Blum, Israel.
11. Dec 2016. "*Klebsiella pneumoniae*: a major world-wide source and shuttle for antibiotic resistance". ISM fall workshop, Ashkelon, Israel.
12. Nov 2015. "Does the gut microbiome shape behavior?" ISM fall workshop, Hagoshrim, Israel.
13. Nov 2013. "The arrival of a hyper virulent MDR *Escherichia coli* in Israel". ISM fall workshop, Zefat, Israel.
14. Mar 2011. "Extended-spectrum β -lactamase-producing *Escherichia coli* bloodstream infections upon hospital admission: molecular epidemiology and virulence traits". European Clinical Microbiology & Infectious Diseases, (ECCMID), Milano, IT.
15. Nov 2010. "Breast implants: methicillin-resistant *Staphylococcus aureus* (MRSA) biofilm model in rats". ISM fall workshop, Genosar, Israel.
16. 2010. "Ceftobiprole medocaril is an effective treatment against methicillin-resistant *Staphylococcus aureus* mediastinitis in a rat model". ISM Annual meeting, Tel Aviv, Israel.
17. 2010. "Methicillin-resistant *Staphylococcus aureus* among dogs and horses in a veterinary hospital". ISM Annual meeting, Tel Aviv, Israel.
18. 2010. "BAL30072, a new sulfactam with excellent in-vitro and in-vivo activity against *Escherichia coli* producing extended-spectrum beta-lactamases". European Clinical Microbiology & Infectious Diseases, (ECCMID), Vienna, AU.

19. 2009. "First report of plasmid-encoded OXA-48 carbapenemase in *Escherichia coli* from Israel". Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), SF, CA USA.
20. 2009. "BAL30376, a promising drug against *Pseudomonas aeruginosa*". ISM Annual meeting, Tel Aviv, Israel.
21. 2008. "Extensively antibiotic-resistant enteric bacteria: what are we dealing with?" ISM fall workshop, Hagoshrim, Israel.
22. 2007. "Emergence of an epidemic clone of KPC-3-producing *Klebsiella pneumoniae* in Israel closely related to an epidemic clone in the US" ICAAC, Chicago, IL USA.
23. 2007. "Co-existence of qnrB-like gene with blaKPC-2 on the same plasmid in carbapenem resistant *Enterobacter cloacae* isolates from Israel" ICAAC, Chicago, IL USA.

(c) Presentations at informal international seminars workshops

1. 2017. "Antibiotic resistance in bacteria causing urinary tract infections in young women in Israel". Health Sciences Faculty Research day, AU.
2. 2014. "The threat of antibiotic resistance". ENEA Italian National Agency for New Technologies, Energy and sustainable economic development, Rome, Italy.
3. 2011. Title of talk: "The real threat of antibiotic resistance-from beta-lactamases to carbapenemases". Israel Institute for Biological Research (IIBR), Nes-Ziona, IL.
4. 2010. Title of talk: "The threat of antibiotic resistance". Host-pathogen Forum, TAU, IL.

- **Research Grants**

2019-2021 Israel Ministry of Science and Space- Shiri Navon-Venezia (PI). Awarded for the project: "Novel cold plasma-based technology for effective prevention and treatment of multidrug resistant catheter-related bacterial infections". 3Y - IS 500,000/year.

2019-2021 Israel Ministry of Health. Shiri Navon-Venezia (PI). Awarded for the project: "Resolving the serum resistance mechanisms in multidrug resistant *Klebsiella pneumoniae* for the development of targeted antibiotics". 2Y - \$56,000.

2018-2019 IDF, Israel Defense Forces, Medical Research- Shiri Navon-Venezia (PI). Awarded for the project: "Emergence of highly virulent multidrug resistant pathogens causing urinary tract infections (UTIs) in Israeli soldiers". 1.5Y- \$35,000.

2017-2020 Israel Ministry of Science and Space- Hanna Rapaport (PI), Shiri Navon-Venezia (Co-PI). Awarded for the project: "Short peptide-based hydrogels as effective antibacterial agents to prevent and treat infections caused by multidrug resistant pathogens". 3Y - \$91,500/year - \$274,300.

2017-2020 ISF, Israel Science Foundation- Shiri Navon-Venezia (PI), Albert Pinhasov (PI). Awarded for the project: "The role of the gut bacterial microbiome in shaping depressive-like behavior: identifying specific markers for behavior prediction and modulation". 3Y - \$70,450/year - \$211,300.

2016-2017 IDF, Israel Defense Forces, Medical Research- Shiri Navon-Venezia (PI), Naty Keller (Co-PI), Tal Brosh (Co-PI), Sharon Amit (Co-PI). Awarded for the project: "Antibiotic resistance causing Urinary Tract Infections in soldiers". 1Y - \$28,200.

2016 ISF, Israel Science Foundation- Institutional equipment grant- Shiri Navon-Venezia (PI), Michael Firer (PI), Gabi Gerlitz (PI). Awarded for cell sorter and ultracentrifuge purchase. \$171,500.

2015-2017 IDF, Medical Research- Shiri Navon-Venezia (PI) & Hanna Rapaport (PI) Awarded for the project: "Development of new treatment for the prevention and treatment of soft and bone infections". 2Y- \$35,200/year - \$70,400.

2014 Ariel Authority of R&D grant, PI. 1Y - \$7,500.

2013-2014 The Samaria and Jordan Rift regional R&D Center. Shiri Navon-Venezia (PI), Shivi Drori (Co-PI). Awarded for the project: "Natural antibiotics from wild flowers effective against human pathogens". 1Y - \$5,600.

2006-2007 Israeli Health Ministry, Chief Scientist - Yehuda Carmeli (PI), Shiri Navon-Venezia (Co-PI). Awarded for the project: "Occurrence of extended-spectrum beta-lactamases in Israel: phenotypic and genotypic characterization". 2Y- \$25,000/year - \$50,000.

2004-2006 CSED, Center for the Study of Emerging Diseases - Shiri Navon-Venezia (PI), Yehuda Carmeli (PI). Awarded for the project: "The epidemiology, mechanisms, and diagnosis of beta-lactam and carbapenem resistant *Pseudomonas aeruginosa*". 2Y- \$30,000/year, \$60,000.

2002-2006 BSF, Binational Science Foundation (Israel-USA) - Shiri Navon-Venezia (PI), Yehuda Carmeli (PI), Howard Gold (PI). Awarded for the project: "Microbiological and epidemiological aspects of extended spectrum beta-lactamases (ESBLs)". 4Y- \$50,000/year - \$200,000.

2000-2001 Ministry of Economy and Industry, "Magnetron". Co-jointed with "Biomedicum Creative Biomedical Computing Ltd" - Amram Mor (PI), Yehuda Carmeli (PI), Shiri Navon-Venezia (CO-PI). "Development of *in-vivo* experimental models for the efficacy studies of antimicrobial peptides". 2Y - \$40,000/year - \$80,000.

- **Present Research students**

1. Oct/2019 – Kler Abir, MSc.
2. Sep/2017 - Oryan Agranyoni, PhD. "The role of the gut bacterial microbiome on shaping behavior" - AU (jointly supervised, Prof. Albert Pinhasov, AU)
3. October/2017 - Ziv Dor, PhD. "Dynamics and duration of carriage of antibiotic resistant gut bacteria in companion animals - AU
4. Jan/2017 - Dr. Dorit Cohen, Postdoc. "Molecular mechanisms of serum resistance in *Klebsiella pneumoniae*" - AU
5. March/2016 - Ayala Gancz, PhD. "The role of extended-spectrum β -Lactamase (ESBL)-encoding plasmids on *Klebsiella pneumoniae* virulence and pathogenesis"- AU
6. October/2016 - Kira Kondratyeva, PhD. "Molecular features and evolution of ESBL-encoding plasmids"- AU
7. October/2016 - Dr. (DVM) Anat Shnaiderman-Torban, PhD. "ESBL-producing *Enterobacteriaceae* in companion animals in Israel: occurrence, epidemiology and molecular characterization". (jointly supervised, Dr. Amir Steinman, HU) - HU